Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Comment by Annayyaon Sep 04, 2020 11:43pm
181 Views
Post# 31514925

RE:DIRECTORS COMPENSATION

RE:DIRECTORS COMPENSATIONIn less than a couple weeks from now, it will be three months since they started their next phase of 'best in class' assay research to find the neutralizing antibodies. With a goal to start manufacturing, marketing and selling the COVID-19 assays as early as Q4, I wonder what's delaying them from completing the research. I just hope they don't announce a stupid PP at 15 measly cents. If these highly paid rich executives care about creating/maintaining value for shareholders and market cap of the company, they can help run the company for a month or so from their own pockets, until they identify the neutralizing antibodies.
TopBroker wrote: Just a note for you who have been following other Companies that have not lived up to their ongoing promises. Shareholders have demanded that non performing management take a reduction in their remuneration and not just foregoing the amounts they receive. When Directors take high amounts of compensation it usually means they do not stand with the shareholders on creating value. I see this being done with several Companies and it usually involves a change in management, which I believe these shareholders need. Depending on if your science is what it is they lead you to believe.


<< Previous
Bullboard Posts
Next >>